Small-Molecule Inhibitors of Protein-Protein Interactions: How to Mimic a Protein Partner

David      C. Fry

doi:10.2174/138161212802651634

Abstract

This systematic review describes successful examples of small-molecule inhibitors of protein-protein interactions, and compares their binding strategies to those employed by the natural protein partners. It extends and updates an earlier survey of this type (Fry DC, Curr Prot Pep Sci 2008; 9: 240-7). From analysis of these systems, common themes and lessons are presented that may assist future drug discovery efforts involving targets in this class. One encouraging finding is that a wide scope appears to be allowed at these sites in terms of binding strategies and chemotypes, which suggests that the outlook for finding small-molecule protein-protein inhibitors is favorable.

Keywords: Protein-protein inhibitor, protein-protein interaction, drug discovery, MDM2, Nutlin, targets, binding strategies, chemotypes, p53, conformation.

« Previous Next »

Download Options

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Small-Molecule Inhibitors of Protein-Protein Interactions: How to Mimic a Protein Partner

Volume: 18 Issue: 30

Author(s): David C. Fry

Affiliation:

Keywords: Protein-protein inhibitor, protein-protein interaction, drug discovery, MDM2, Nutlin, targets, binding strategies, chemotypes, p53, conformation.

Abstract: This systematic review describes successful examples of small-molecule inhibitors of protein-protein interactions, and compares their binding strategies to those employed by the natural protein partners. It extends and updates an earlier survey of this type (Fry DC, Curr Prot Pep Sci 2008; 9: 240-7). From analysis of these systems, common themes and lessons are presented that may assist future drug discovery efforts involving targets in this class. One encouraging finding is that a wide scope appears to be allowed at these sites in terms of binding strategies and chemotypes, which suggests that the outlook for finding small-molecule protein-protein inhibitors is favorable.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

C. Fry David, Small-Molecule Inhibitors of Protein-Protein Interactions: How to Mimic a Protein Partner, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651634

DOI https://dx.doi.org/10.2174/138161212802651634	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

About this journal

Call for Papers in Thematic Issues

Submission closes on : 09 May, 2026

"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"

The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more

Guest Editor(s): Dr. Smriti Sharma

Submission closes on : 31 July, 2026

Accelerating Cancer drug discovery using Artificial intelligence and In Silico methods

The Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how ...read more

Guest Editor(s): Dr. Dileep Kumar

Submission closes on : 31 December, 2025

Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.

This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more

Guest Editor(s): Dr. Manish Gautam

Submission closes on : 16 July, 2026

Artificial Intelligence and Computational Approaches in Drug Discovery

Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more

Guest Editor(s): Dr. Yang Zhang